Abstract Library

#4237 Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumor pAtients (SAUNA trial) – Study protocol for a bi-national, multi-center, open-label, randomised, pragmatic clinical trial

Introduction: Advanced gastroenteropancreatic neuroendocrine tumors (GEP NET) are treated with targeted therapy or peptide receptor radionuclide therapy (PRRT) (177Lu-DOTATATE) upon progression under somatostatin analogues (SSA). SSA are continued life-long in functional NET, but the benefit of SSA continuation in non-functional NET is unclear. Due to ongoing activity of the somatostatin receptor pathway in GEP NET progressing on SSA, we hypothesize an added efficacy of SSA during second-line therapy.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Kuiper J, Borbath I, Dercksen W, Deroose C,

Keywords: somatostatin analogues, SSA, everolimus, sunitinib, peptide receptor radionuclide therapy, PRRT, quality of life, QoL, gastroenteropancreatic neuroendocrine tumor, GEP NET,

#4221 Assessing the frequency of type I gastric neuroendocrine neoplasms in autoimmune atrophic gastritis: A multi-center study in Italy

Introduction: In autoimmune atrophic gastritis (AAG), mucosa morpho-functional changes lead to hypo-achlorhydria, hypergastrinemia, and enterochromaffin-like (ECL) cells proliferation, escalating the risk of type I gastric neuroendocrine neoplasms (gNENs). Longitudinal studies on the AAG-gNENs association are scanty.

Conference:

Presenting Author: Gallo C

Authors: Massironi S, Gallo C, Lahner E, Sciola V, Cavalcoli F,

Keywords: neuroendocrine tumor, atrophic gastritis, autoimmune gastritis, gastrin,

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,

#4067 Malignancy of gastric neuroendocrine tumors is higher than pancreatic neuroendocrine tumors in Chinese population – Characterisation and analysis of factors

Introduction: Based on a large-scale epidemiological survey with a total of 2010 cases of neuroendocrine tumors (NENs) in the Chinese population from multiple centers, we observed that the malignancy of gastric NENs (G3, accounting for 67.2%) is higher than that of pancreatic NENs(G3, accounting for 9.9%).

Conference:

Presenting Author: Sun W

Authors: Sun W, Fan J,

Keywords: gastric NEN, pancreatic NEN, epidemiology, multi-center,

#3522 Clinical epidemiology of upper gastrointestinal neuroendocrine neoplasms (UGI-NENs): A nationwide multi-center 10-year retrospective study

Introduction: The upper gastrointestinal neuroendocrine neoplasms (UGI-NEN) are the most common endocrine neoplasms (NEN), and the incidence has increased rapidly in recent years.

Conference:

Presenting Author: Wang X

Authors: Wang X, Yang H, Chi Y, Fan J,

Keywords: upper gastrointestinal neuroendocrine neoplasm, retrospective study, multi-center, clinical epidemiology,